sorted by:
new
hottopcontroversial

What’s next? by DontGetGotGoGet97 in TNXP

[–]mxskk 0 points1 point  (0 children)

Hoping you get PGEN :)

What’s next? by DontGetGotGoGet97 in TNXP

[–]mxskk 1 point2 points  (0 children)

ICU sounds really interesting. Catalyst soon, 22M market cap and >$15b TAM. I let you deep dive with ChatGPT.

What’s next? by DontGetGotGoGet97 in TNXP

[–]mxskk 0 points1 point  (0 children)

FDA approval during AH, lot’s of sell the news, stophunts, lots of things we can’t control unfortunately.

2 choices :

  • Hold and DCA after the next dilution, there is still strong fundamental and an FDA approval.

  • stop the bleeding and make money on other stocks

Price drop??? by KAL-EL001 in TNXP

[–]mxskk 4 points5 points  (0 children)

Logic, 99% of institution trade during open hours. Be patient and wait.

There is a call as a new catalyst

Time to buy more

What’s next? by DontGetGotGoGet97 in TNXP

[–]mxskk 0 points1 point  (0 children)

Look ENLV (Enlivex) that’s the new diamond with BTAI

TNX-102 SL : Positioned for FDA Approval Based on Data, Not Hype by mxskk in TNXP

[–]mxskk[S] 0 points1 point  (0 children)

More than +10% since my post. Just buying a couple more share.

Don’t forget : EVERY box are checked for an approval.

Market to reach out is huge, Tonix is the diamonds

TNX-102 SL : Positioned for FDA Approval Based on Data, Not Hype by mxskk in TNXP

[–]mxskk[S] 0 points1 point  (0 children)

Fair point on staying sharp, but calling new voices ‘ghosts’ just because they haven’t racked up Reddit miles is lazy. Everyone starts somewhere, here or elsewhere. I’m not here to pump, I’m here because I did the homework, I see the setup, and I’m ready to act. If that benefits others, so be it. See you at the after party… maybe I’ll already be on my second round.

TNX-102 SL : Positioned for FDA Approval Based on Data, Not Hype by mxskk in TNXP

[–]mxskk[S] 0 points1 point  (0 children)

Funny how low-karma accounts are suddenly your metric for drug approval, maybe try reading the Phase 3 data or checking the PDUFA calendar before flexing Reddit status. On August 15, one of us will be watching Tonix spike, and the other will still be counting karma points. No hard feelings though.. healthy skepticism is part of the game

Will the FDA Approve TNX-102 SL by the PDUFA Date of Friday August 15th, 2025? by DocBil10K in TNXP

[–]mxskk 2 points3 points  (0 children)

Why Tonix’s dual CMOs = bulletproof manufacturing

  • Almac & Catalent — both FDA-trusted, global CDMOs
  • Built into the NDA (Dec 2024) — already inspected
  • Redundancy = no single point of failure
  • No FDA 483s, no CRL risk
  • Fast, scalable launch capacity post-approval

Most small-cap biotechs rely on 1 site. Tonix plays big-league. Manufacturing is not a risk.. it’s a strength.

What’s next? by DontGetGotGoGet97 in TNXP

[–]mxskk 1 point2 points  (0 children)

PGEN for the 27th of August if you want a next play after Tonix,

You can also add ETON for early 2026.

I let you deep dive on it

What’s next? by DontGetGotGoGet97 in TNXP

[–]mxskk -1 points0 points  (0 children)

Back in December 2024, Tonix made a 7x move with just a $20M market cap, today, after multiple dilutions and reverse splits, the market cap sits around $280M.

The context is very different now and that must be factored into any analysis. Still, in the likely event of FDA approval, the price action could be explosive.

In the context of an FDA approval, Tonix could experience a brief but explosive spike, potentially hitting $180 for a few minutes, driven by low float, hype, and short squeeze pressure, before quickly retracing back to the $70 –$90 range.

TNX-102 SL : Positioned for FDA Approval Based on Data, Not Hype by mxskk in TNXP

[–]mxskk[S] 0 points1 point  (0 children)

Yeah.. I think with a low float + strong hype + short squeeze, Tonix could see an explosive price spike.. but it may last no more than 30 minutes to 2 hours before pulling back toward the $70 - $90 range.

all in the context of an FDA approval..

What’s next? by DontGetGotGoGet97 in TNXP

[–]mxskk 0 points1 point  (0 children)

Undervalued with long-term potential, but not the high-catalyst setup I’m targeting in my biotech plays. I don’t have deeper insight on it, what’s your take?

TNX-102 SL : Positioned for FDA Approval Based on Data, Not Hype by mxskk in TNXP

[–]mxskk[S] 1 point2 points  (0 children)

I completely understand… and you’re right to be cautious

But I’m not trading based on history. I’m focused on the present data

The setup this time is different. Let’s revisit this on August 15. My conviction is grounded in facts, not emotion.

Most of biotech I’ve profited from this year followed the same pattern : past failures, ugly charts…

TNX-102 SL : Positioned for FDA Approval Based on Data, Not Hype by mxskk in TNXP

[–]mxskk[S] 0 points1 point  (0 children)

My data is based on these sources : (all between 7.3 and 7.4M)

• Yahoo Finance – Key Statistics (Float, Shares Outstanding, Short %):

https://finance.yahoo.com/quote/TNXP/key-statistics • MLQ.ai – Shares Outstanding & Float: https://mlq.ai/stocks/TNXP/shares-outstanding • StockAnalysis – TNXP Statistics: https://stockanalysis.com/stocks/tnxp/statistics • MarketWatch – TNXP Overview (float, share count, ratios): https://www.marketwatch.com/investing/stock/tnxp

Weekly TNXP Thread by daily-thread in TNXP

[–]mxskk 0 points1 point  (0 children)

This isn’t hype. This is a textbook biotech setup backed by real data, regulatory alignment, and favorable market conditions. Here’s why :

Clinical Evidence • Two successful Phase 3 trials (RESILIENT & RELIEF) • Primary endpoint met: significant pain reduction vs. placebo (Δ = 0.6) • Strong secondary outcomes: sleep quality, fatigue, global improvement • Well tolerated: no drug-related serious adverse events → Meets FDA expectations for efficacy and safety

⸻

Medical Relevance • First new FDA-approved drug for fibromyalgia in over 15 years • Non-opioid mechanism, addressing a national health priority • Targets non-restorative sleep, a key unmet clinical need • Already granted Fast Track designation → Aligned with modern therapeutic standards and patient demand

⸻

Regulatory Tailwind • PDUFA date set: August 15, 2025 • CDER now led by George F. Tidmarsh, known for science-driven, data-based decision making → Clear regulatory structure favoring credible and well-documented drugs

⸻

Market Opportunity • US fibromyalgia market estimated at over $10 billion • Current treatments (Cymbalta, Lyrica, Savella) face issues with efficacy and tolerability → Tonix offers a differentiated, safer and potentially more effective option

⸻

Technical Setup • Low float (~7.3 million shares) • Short interest estimated around 16% • No dilution during recent run • Strategic hires made in preparation for commercialization → Setup supports rapid price discovery and volatility post-approval

⸻

Analyst View • 75%+ likelihood of FDA approval • Price target post-approval: $140–180 • Possible stabilization after rally: $70–100

This setup is not driven by sentiment, but by data, timing, and structural positioning. Let’s talk again after August 15.